Navigation Links
Warner Chilcott Completes Acquisition of P&G's Global Branded Prescription Pharmaceuticals Business
Date:10/30/2009

ARDEE, Ireland, Oct. 30 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) announced today it has completed the acquisition of The Procter & Gamble Company's global branded prescription pharmaceutical business. The acquisition complements Warner Chilcott's existing presence in women's health care and adds new therapeutic and geographic markets. At closing approximately 1,900 employees of P&G's pharmaceuticals business joined Warner Chilcott and the Company added manufacturing facilities in Germany and Puerto Rico.

"This is a transformational acquisition that extends our presence to include many of the major pharmaceutical markets around the World and significantly enhances the scale and diversity of our business," said Roger Boissonneault, President and Chief Executive Officer of Warner Chilcott. "Importantly, the increased scale afforded by this deal provides us with the ability to pursue a broader range of R&D projects to fuel our long-term growth."

To finance the acquisition, the Company used a combination of cash on hand and borrowings under new senior secured credit facilities. The new senior secured credit facilities provided for $3.2 billion in financing and are comprised of a $250 million revolving credit facility with a five-year maturity, a $1.0 billion Term Loan A with a five year maturity, a $1.6 billion Term Loan B with a five-and-a-half year maturity and a $350 million delayed-draw Term Loan B with a five-and-a-half year maturity. Borrowings under the Term Loan A and revolving credit facility bear interest at LIBOR plus 3.25% and under the Term Loan B and delayed-draw facility at LIBOR plus 3.50%, in all cases subject to a 2.25% floor on LIBOR. At the closing, the Company borrowed a total of $2.6 billion under the term loan facilities and did not borrow under the revolving credit facility or the delayed-draw term loan facility. The Company's existing $380 million aggregate principal amount of 8 3/4% senior subordinated notes remain outstanding.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare, gastroenterology, dermatology and urology segments of the U.S. and Western European pharmaceuticals market. It is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-G

SOURCE Warner Chilcott plc


'/>"/>
SOURCE Warner Chilcott plc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
2. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
Breaking Medicine News(10 mins):